nach oben

Pathology & Oncology Research

Erschienen in:

01.09.2011 | Research

Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population

verfasst von: Syed Jafar Mehdi, Asgar Ali, M. Moshahid Alam Rizvi

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Parkin, a tumor suppressor gene located on chromosome 6q25-27, has been identified as a target for mutation in many human malignancies like breast, ovaries, cervical and lungs etc. After a preliminary report on the loss of heterozygosity and altered Parkin expression in breast and ovarian tumors, we aimed to study loss of heterozygosity in the Parkin gene associated microsatellite markers and its expression in human ovarian cancer patients from Indian population. We examined 102 paired normal and ovarian cancer samples for allelic loss in Parkin gene locus using Parkin gene associated microsatellite markers through loss of heterozygosity and changes in its expression through semiquantitative RT-PCR. Loss of heterozygosity identified common region of loss in Parkin locus with highest frequency for the intragenic marker D6S1599 (53%) whereas, 49 of 102 (48%) specimens showed decreased or no expression of Parkin in ovarian tumors. The study revealed that presence of loss of heterozygosity was significantly higher in both the intragenic markers (D6S1599 and D6S305) as compared with the locus of flanking region (D6S1008) with their p value 0.000001 and 0.00008, respectively. It also revealed that Parkin inactivation is probably a combination of loss of heterozygosity coupled with downregulation of Parkin gene through an alternative means like epigenetic mechanism. These data strongly supports the previous study and argue that Parkin is a tumor suppressor gene whose inactivation may play an important role in ovarian carcinoma.

Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. Cancer J Clin 48:6–29CrossRef

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96PubMedCrossRef

Boyle P, Levin B (2008) International Agency for Research on Cancer, and World Health Organization, “World cancer report 2008.” Distributed by WHO Press, Geneva, Switzerland

American Cancer Society. Facts & Figures 2009

GLOBOCAN (2008) Cancer incidence, mortality and prevalence worldwide. IARC 2008. IARC, Lyon

Theile M, Seitz S, Arnold W, Jandrig B, Frege R, Schlag PM, Haensch W, Guski H, Winzer KJ, Barrett JC, Scherneck S (1996) A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene 13:677–685PubMed

Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58:2170–2175PubMed

Reutzel D, Mende M, Naumann S, Störkel S, Brenner W, Zabel B, Decker J (2001) Genomic imbalances in 61 renal cancers from the proximal tubulus detected by comparative genomic hybridization. Cytogenet Cell Genet 93:221–227PubMedCrossRef

Jin C, Martins C, Jin Y, Wiegant J, Wennerberg J, Dictor M, Gisselsson D, Strömbeck B, Fonseca I, Mitelman F, Tanke HJ, Hoglund M, Mertens F (2001) Characterization of chromosome aberrations in salivary gland tumors by FISH, including multicolor COBRA-FISH. Genes Chromosome Cancer 30:161–167CrossRef

10.

Jackson A, Carrara P, Duke V, Sinclair P, Papaioannou M, Harrison CJ, Foroni L (2000) Deletion of 6q16–q21 in human lymphoid malignancies: a mapping and deletion analysis. Cancer Res 60:2775–2779PubMed

11.

Carvalho B, Veen AY, Gärtner F, Carneiro F, Seruca R, Buys CHCM, Kok K (2001) Allelic gains and losses in distinct regions of chromosome 6 in gastric carcinoma. Cancer Genet Cytogenet 131(1):54–59PubMedCrossRef

12.

De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL (1995) Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10(9):1725–1729PubMed

13.

Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB, Sidransky D (1994) Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 54:2322–2326PubMed

14.

Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP (1995) Genetic changes in primary reccurent prostate cancer by comparative genomic hybridization. Cancer Res 55:342–347PubMed

15.

Tahara H, Smith AP, Gaz RD, Cryns VL, Arnold A (1996) Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 56:599–605PubMed

16.

Sebsebe L, Lea P, Markku S, Mika N, Sirkku S, Kirsti HP, Tom B (2004) Loss of Heterozygosity at 6q is frequent and concurrent with 3p loss in sporadic and familial capillary hemangioblastomas. J Neuropathol Exp Neurol 63(10):1072–1079

17.

Inoue M, Marx A, Zettl A, Ströbel P, Müller-Hermelink HK, Starostik P (2002) Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 161(4):1507–1513PubMedCrossRef

18.

Mazurenko NN, Beliakov IS, Bliyev AY, Guo Z, Hu X, Vinokourova SV, Bidzhieva BA, Pavlova LS, Ponten J, Kisseljov FL (2003) Genetic alterations at chromosome 6 associated with cervical cancer progression. Mol Biol 37(3):404–411CrossRef

19.

Wan M, Sun T, Vyas R, Zheng J, Granada E, Dubeau L (1999) Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24–q25. Oncogene 18:1545–1551PubMedCrossRef

20.

Sheng ZM, Marchetti A, Buttitta F, Champeme MH, Campani D, Bistocchi M, Lidereau R, Callahan R (1996) Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer 73:144–147PubMedCrossRef

21.

Colitti CV, Rodabaugh KJ, Welch WR, Berkowitz RS, Mok SC (1998) A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinoma. Oncogene 16:555–559PubMedCrossRef

22.

Tibiletti MG, Bernasconi B, Furlan D, Riva C, Trubia M, Buraggi G, Franchi M, Bolis P, Mariani A, Frigerio L, Capella C, Taramelli R (1996) Early involvement of 6q in surface epithelial ovarian tumors. Cancer Res 56:4493–4498PubMed

23.

Cooke IE, Shelling AN, Le Meuth VG, Charnock ML, Ganesan TS (1996) Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chromosom Cancer 15:223–233PubMedCrossRef

24.

Tibiletti MG, Trubia M, Ponti E, Sessa L, Acquati F, Furlan D, Bernasconi B, Fichera M, Mihalich A, Ziegler A, Volz A, Facco C (1998) Physical map of the D6S149–D6S193 region on chromosome 6Q27 and its involvement in benign surface epithelial ovarian tumours. Oncogene 16:1639–1642PubMedCrossRef

25.

Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (Lond) 392:605–608CrossRef

26.

Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, d’Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM (2003) Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27. Proc Natl Acad Sci USA 100:5956–5961PubMedCrossRef

27.

Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI (2003) Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosom Cancer 38:40–52PubMedCrossRef

28.

West A, Periquet M, Lincoln S, Lucking CB, Nicholl D, Bonifati V, Rawal N, Gasser T, Lohmann E, Hardy J, Brice A, Farrer M (2002) Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet 114:584–591PubMedCrossRef

29.

Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR, Fishel R, Croce CM (2004) Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10:2720–2724PubMedCrossRef

30.

Mehdi SJ, Alam MS, Batra S, Rizvi MMA (2010) Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma. Medical Oncology (in press). doi:10.1007/s/12032-010-9633-x

31.

Denison SR, Wang F, Becker NA, Schüle B, Kock N, Phillips LA, Klein C, Smith DI (2003) Genetic alteration in the common fragile site gene PARK2 in ovarian and other cancers. Oncogene 22:8370–8378PubMedCrossRef

32.

Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N, Schüle B, Klein C, Shridhar V, Roberts LR, Smith DI (2004) Parkin gene alterations in hepatocellular carcinoma. Genes Chromosom Cancer 40:85–96PubMedCrossRef

33.

Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA (2010) Somatic mutations of the Parkinson’s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42(1):77–82PubMedCrossRef

34.

Benedet JL, Bender H, Jones H III, Ngan HYS, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 70:209–262CrossRef

35.

Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual, 3rd edn. Cold Spring Harbor Lab, Plainview

36.

Yuping X, Lili M, Chengbo H, Jinyi L, Lei X, Yan X (2007) MSI/LOH and extron expression of the FHIT gene in gastric carcinoma. Front Med China 1(1):99–103CrossRef

37.

Preacher KJ (2001) Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]. Available from http://www.quantpsy.org

38.

Foulkes WD, Ragoussis J, Stamp GWH, Allan GJ, Trowsdale J (1993) Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 67:551–559PubMedCrossRef

39.

Wan MZT, D’Abling G, Zheng I, Veliscu M, Dubeau L (1994) Three distinct regions of chromosome 6 are targets of loss of heterozygosity in human ovarian carcinomas. J Oncol 5:1043–1048

40.

Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F (2006) Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 118:1945–1953PubMedCrossRef

Titel: Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population
verfasst von: Syed Jafar Mehdi
Asgar Ali
M. Moshahid Alam Rizvi
Publikationsdatum: 01.09.2011
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 3/2011
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-010-9351-x

Springer Medizin

Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Female Breast Cancer Status According to ER, PR and HER2 Expression: A Population Based Analysis

Expression of Tankyrase 1 in Gastric Cancer and Its Correlation with Telomerase Activity

Primary Peritoneal Serous Papillary Carcinoma: A Clinical and Pathological Study

Relationship Between Hypermethylated MGMT Gene and Osteosarcoma Necrosis Rate After Chemotherapy

Lymphoproliferative Disorders After Solid Organ Transplantation—Classification, Incidence, Risk Factors, Early Detection and Treatment Options

Detection of APC Gene Deletions in Colorectal Malignancies Using Quantitative PCR in a Chinese Population

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie